about imbioray
Imbioray is a clinical-stage innovative biopharmaceutical company, the pioneer of generic off-the-shelf trained-immunity NK cells, dedicated to the research, development, and clinical application in the cell field. It has achieved comprehensive applications of ACC-NK (antibody-cell conjugate NK), ATE-NK (antibody-targeted enhanced NK), and tiNK (trained-immunity NK) in solid and hematological tumors, various non-oncological diseases, and health management.
Imbioray owns cutting-edge patented technology for NK cell immunity training and a world-class large-scale GMP production center. It is an industry standard-setter for the entire chain of NK cell preparation—from raw material collection to release and clinical application. With its high technology, efficiency, and quality, it has become a representative enterprise of national "New Quality Productive Forces."
Dedicated to NK Cell Research
R&D Talents
Honors at Home and Abroad
IND & Biomedical New Technologies
Number and Progress of Clinical Trial Projects
Development History
Honors and Qualifications
global layout
Over 300 Professional Marketing Staff
The company's operations now cover 31 provinces and regions across China.
global layout
Operations have expanded to the United States, Japan, Southeast Asia, Europe, the Middle East, 13 African countries, and the Caribbean region.
Scan the QR code to learn more
Consultation Hotline400-995-9976
Copyright2025 英百瑞（杭州）医学研究有限公司 All Rights Reserved. 浙ICP备2025205905号 DESIGN BY : WEETOP
